Sign in
Taking people in United StatesPhase 1/2

Tests AZD4512 alone or with other cancer drugs in acute lymphoblastic leukemia

Tests AZD4512 in people with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia.

Key facts

Who runs it
AstraZeneca
Where
Chicago, Duarte, Franklin, Houston, Iowa City, and Jacksonville, United StatesSee the 6 sitesAlso in 8 other countries, 17 sites
Registry title
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
Status
Recruiting
Phase
Phase 1/2
People taking part
83 people, planned
Started
12 Nov 2025
Expected to end
18 Jul 2029
Type of study
Interventional, 2 groups
Treatments tested
  • AZD4512 monotherapy
Record updated
13 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or did not respond to treatment, and whose leukemia cells carry CD22.

Age
From 12 years. Module 1: 16 years or older (18 years or older in the US only). Module 2: 12 years or older.
Sex
All sexes can join.
Disease stage
Relapsed or refractory CD22-positive B-ALL, confirmed by WHO criteria. Relapse means bone marrow blasts above 5% or blasts back in the blood. Blood lymphoblast count must be under 10,000/µL.
Earlier treatment
Module 1 dose-escalation: at least 2 earlier treatments that failed or the disease returned, or 1 failed treatment with no standard option left. Other parts: at least 1 earlier treatment that failed or the disease returned. Waiting times apply after donor lymphocyte infusion, cell therapy and stem cell transplant.
Biomarker or test result
CD22-positive B-ALL. For most participants CD22 must be shown by a local test at screening. Ph-positive disease is allowed only in Module 1 dose-escalation.

Main reasons for not taking part

  • Burkitt lymphoma or leukemia
  • Disease only outside the bone marrow, or active testicular or CNS involvement
  • History of drug-induced lung inflammation (ILD/pneumonitis) needing steroids or oxygen
  • Unresolved non-blood side effects of Grade 2 or higher from earlier treatment
  • Recent chemotherapy, biologic therapy, radiation or investigational drugs within set time limits

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • 1. Age:; 16 years old in Module 1 (US only: ≥18year); 12 years old in Module 2; Diagnosis: Known Diagnosis of CD22-positive B-ALL based on criteria established by WHO (Alaggio et al. 2022)
  • All Participants must have relapsed or refractory B-ALL ('relapsed' defined as bone marrow blasts > 5% or reappearance of blasts in PB)
  • Module 1 (DE): R/R B-ALL [Ph(-) and Ph(+)]
  • Backfill of Module 1 and Module 2 (DO): R/R B-ALL [Ph(-)] with demonstration of CD22 expression by local assessment in screening; Performance status (ECOG ≤ 2; KPS ≥ 50; LPS ≥ 50); Peripheral lymphoblast count < 10,000/µL (may receive cytoreduction prior to C1D1 per protocol-specified criteria); Prior therapies:
  • Module 1 (DE): At least 2 prior therapies with refractoriness or relapse, or 1 prior therapy with refractoriness or relapse and no standard options available. For Ph+ B-ALL: intolerant to or have contraindications to TKI therapy or R/R disease despite treatment with at least 2 prior TKIs or at least one 3rd generation TKI
  • Backfill of Module 1 (backfills) and Module 2 (DO): at least one prior line of therapy (SOC or clinical trial) to which the participant has been either refractory or has subsequently relapsed
  • Participants who have received prior CD22 targeted therapies and were not refractory to these therapies are eligible; Prior DLI >4 weeks, prior cell therapy or autoHSCT >8 weeks, alloHSCT >12 weeks

Who cannot take part

  • Isolated extramedullary disease; Active testicular or CNS (> CNS1) involvement
  • Unresolved non-heme toxicities Grade ≥ 2 (except alopecia, stable Grade ≤ 2 neuropathy, vitiligo, endocrine disorders controlled with therapy)
  • History of drug-induced non-infectious ILD/pneumonitis requiring oral or IV steroids or supplemental oxygen or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening
  • Prior/concomitant therapy; Cytotoxic treatment within 14 days (except ALL maintenance medications or cytoreduction); Biologic (immuno-oncology) treatment within 28 days or 5 half-lives (whichever is shorter); Non-CNS radiation within 2 weeks \& CNS radiation within 4 weeks; Medications known to prolong QTc and/or associated with Torsades de Pointes within 5 half-lives; Strong inhibitors of CYP 3A4 within 14 days or 5 half-lives (whichever is longer); Investigational agents or study interventions in the last 30 days or 5 half-lives prior to the first dose of AZD4512 whichever is longer; If the investigational product is an agent to treat B-ALL and meets the modality criteria, then a specific washout period must be adhered to instead
  • Burkitt lymphoma and leukemia

Where in United States

Also in 8 other countries, 17 sites

  • Chicago, IllinoisHospital not named in the registryTaking people
  • Duarte, CaliforniaHospital not named in the registryTaking people
  • Franklin, TennesseeHospital not named in the registryTaking people
  • Houston, TexasHospital not named in the registryTaking people
  • Iowa City, IowaHospital not named in the registryTaking people
  • Jacksonville, FloridaHospital not named in the registryNo longer taking part

About the trial

What the trial wants to find out

The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AZD4512 in patients with relapsed/refractory B-Cell acute lymphoblastic leukemia (r/r B-ALL).

The 2 groups in the trial

  • Module 1 Dose EscalationTreatment being tested

    Module 1 will evaluate escalating doses of AZD4512 as monotherapy to determine the maximum tolerated dose (MTD) and/or doses of AZD4512 for subsequent evaluation in Module 2 (dose optimization), in participants with relapsed/refractory (R/R) Philadelphia chromosome positive (Ph\[+\]) and negative (Ph\[-\]) B-ALL, R/R as defined by National Comprehensive Cancer Network (NCCN) guidelines.

    Treatment: AZD4512 monotherapy

  • Module 2 Dose OptimizationTreatment being tested

    Module 2 will randomize participants with R/R (as defined by NCCN guidelines) Ph(-) BALL only across 2 to 3 dose levels identified in Module 1 to receive AZD4512 monotherapy for further exploration of the doses. The aim of Module 2 is to identify the recommended Phase 2 dose (RP2D) of AZD4512 monotherapy, evaluate the efficacy and further define the safety profile of AZD4512.

    Treatment: AZD4512 monotherapy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Modular Phase I/II, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of AZD4512 Monotherapy or in Combination With Anticancer Agent(s) in Participants With Acute Lymphoblastic Leukemia
Plain-language title
Tests AZD4512 alone or with other cancer drugs in acute lymphoblastic leukemiaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
13 November 2026